AJOVY Drug Insight

“AJOVY Market Size, Forecast, and Drug Insight – 2032” report offers an in-depth analysis of both the market and emerging insights regarding AJOVY for the treatment of Migraine and Chronic pain in the seven major markets. A detailed picture of the AJOVY in the 7MM, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan for the study period 2019 –2032 is provided in this report along with a detailed description of the AJOVY. The report provides insights about mechanism of action, dosage and administration, as well as research and development including regulatory milestones, along with other developmental activities. Further, it also consists of future market assessments, including the AJOVY market forecast analysis in the 7MM, SWOT, analysts’ views, a comprehensive overview of market competitors, and a brief about other emerging therapies.

Drug Summary

AJOVY (fremanezumab-vfrm) is a fully humanized IgG2Δa/kappa monoclonal antibody specific for CGRP ligand. Fremanezumab-vfrm, or fremanezumab, is produced by recombinant DNA technology in CHO cells. The antibody consists of 1,324 amino acids and has a molecular weight of approximately 148 kDa.

Fremanezumab targets both α and β isoforms of the CGRP ligand (not the receptor), has flexible dosing, and is administered using SC injection (Silberstein et al., 2017). It is also in clinical development to evaluate safety and efficacy in treating post-traumatic headache and fibromyalgia.

Dosage and administration

• Two SC dosing options of AJOVY are available to administer the recommended dosage:
• 225 mg monthly, or
• 675 mg every 3 months (quarterly), which is administered as three consecutive SC injections of 225 mg each
• When switching dosage options, administer the first dose of the new regimen on the next scheduled administration date. If a dose of AJOVY is missed, administer it as soon as possible. Thereafter, AJOVY can be scheduled from the date of the last dose.

Dosage form and strength

• It is given in injection form of strength 225 mg/1.5 mL solution in a single-dose prefilled syringe.
• Mechanism of action
• Fremanezumab-vfrm is a humanized monoclonal antibody that binds to the CGRP ligand and blocks its binding to the receptor.

Scope of the Report

The report provides insights into:

• A comprehensive product overview includes the AJOVY description, mechanism of action, dosage and administration, and research and development activities in migraine and chronic pain.
• Elaborated details on AJOVY regulatory milestones and other development activities have been provided in this report.
• The report also highlights the AJOVY research and development activities in Migraine and Chronic pain across the United States, Europe and Japan.
• The report also covers the patents information with expiry timeline around AJOVY.
• The report contains forecasted sales of for Migraine and Chronic pain till 2032.
• Comprehensive coverage of the late-stage emerging therapies for Migraine and Chronic pain.
• The report also features the SWOT analysis with analyst views for AJOVY in Migraine and Chronic pain.

Methodology

The report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight’s team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities' websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals, and access to available databases.

AJOVY Analytical Perspective by DelveInsight

• In-depth AJOVY Market Assessment

This report provides a detailed market assessment of AJOVY for Migraine and Chronic pain in the seven major markets, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan. This segment of the report provides forecasted sales data from 2023 to 2032.

• AJOVY Clinical Assessment

The report provides the clinical trials information of AJOVY for Migraine and Chronic pain covering trial interventions, trial conditions, trial status, start and completion dates.

Report Highlights 

• In the coming years, the market scenario for Migraine and Chronic pain is set to change due to the extensive research and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.  
• Companies are developing therapies that focus on novel approaches to treat/improve disease conditions, assess challenges, and seek opportunities that could influence AJOVY dominance.
• Other emerging products for migraine and chronic pain are expected to give AJOVY tough market competition, and the launch of late-stage emerging therapies in the near future will significantly impact the market.
• A detailed description of regulatory milestones and developmental activities provides the current development scenario of AJOVY in Migraine and Chronic pain.
• Our in-depth analysis of the forecasted sales data of AJOVY from 2023 to 2032 will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of AJOVY in Migraine and Chronic pain.

Key Questions

• What is the product type, route of administration, and mechanism of action of AJOVY?
• What is the clinical trial status of the study related to AJOVY in Migraine and Chronic pain, and the study completion date?
• What are the key collaborations, mergers, acquisitions, licensing, and other activities related to the AJOVY development?
• What are the key designations that have been granted to AJOVY for Migraine and Chronic pain?
• What is the forecasted market scenario of AJOVY for Migraine and Chronic pain?
• What are the forecasted sales of AJOVY in the seven major countries, including the United States, Europe (Germany, France, Italy, Spain, and the United Kingdom), and Japan? 
• What are the other emerging products available, and how are these giving competition to AJOVY for Migraine and Chronic pain?
• Which are the late-stage emerging therapies under development for the treatment of Migraine and Chronic pain?